A Follow-up Study to Assess the Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 26 Jan 2016 Planned initiation date changed from 1 Oct 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.